CDTX - Cidara Therapeutics's drug candidates show encouraging action against fungal and viral infections

Cidara Therapeutics ([[CDTX]] +1.0%) has announced new data from Phase 2 STRIVE trial of rezafungin, echinocandin for treatment and prevention of fungal infections, and CD377 preclinical data for influenza protection. Data were presented at IDWeek 2020.New analyses from completed Phase 2 trial support the efficacy and pharmacokinetics of once-weekly rezafungin, across a wide array of patient populations. The trial demonstrated efficacy across multiple Candida species, with similar or better outcomes observed with rezafungin compared to standard of care, caspofungin.In preclinical studies, a single dose of CD377 was protective against seasonal and pandemic influenza subtypes, demonstrating its potent broad-spectrum activity. Showed  superior dose-dependent viral load reduction in the lung compared to approved influenza treatment oseltamivir.

For further details see:

Cidara Therapeutics's drug candidates show encouraging action against fungal and viral infections